HER2-Low Breast Cancer—Diagnostic Challenges and Opportunities for Insights from Ongoing Studies: A Podcast Aditya BardiaGiuseppe Viale Commentary Open access 03 May 2023 Pages: 313 - 319
P-REALITY X: A Real-World Analysis of Palbociclib Plus an Aromatase Inhibitor in HR+/HER2− Metastatic Breast Cancer—A Podcast Adam BrufskyChristopher Gallagher Commentary Open access 06 May 2023 Pages: 321 - 326
Place in Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: A Targeted Literature Review Melody ZhaoKent A. HansonAshley S. Cha-Silva Review Article Open access 19 April 2023 Pages: 327 - 358
A Multicenter, Phase II Trial of Schedule Modification for Nab-Paclitaxel in Combination with Ramucirumab for Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: The B-RAX Trial (JACCRO GC-09) Ryohei KawabataNaoki IzawaMasashi Fujii Original Research Article 15 April 2023 Pages: 359 - 368
A Phase II Trial of Trifluridine/Tipiracil in Combination with Cetuximab Rechallenge in Patients with RAS Wild-Type mCRC Refractory to Prior Anti-EGFR Antibodies: WJOG8916G Trial Naoki IzawaToshiki MasuishiKei Muro Original Research Article 06 May 2023 Pages: 369 - 381
A Phase I Clinical Trial Evaluating the Safety and Dosing of Relugolix with Novel Hormonal Therapy for the Treatment of Advanced Prostate Cancer Jose De La CerdaCurtis DunsheeNeal Shore Original Research Article Open access 15 April 2023 Pages: 383 - 390
A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory Solid Tumors and Hematological Malignancies Cheng E. CheeMelissa OoiBoon-Cher Goh Original Research Article Open access 15 April 2023 Pages: 391 - 402
Comparison of Cerebral Blood Flow in Regions Relevant to Cognition After Enzalutamide, Darolutamide, and Placebo in Healthy Volunteers: A Randomized Crossover Trial Steven C. R. WilliamsNdaba MazibukoPatricia E. Cole Original Research Article Open access 27 April 2023 Pages: 403 - 413
Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST): The Dutch GIST Registry Data Mahmoud MohammadiNikki S. IJzermanHans Gelderblom Original Research Article Open access 20 April 2023 Pages: 415 - 423
Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort Study Diego F. ChamorroAndrés F. CardonaCLICaP Original Research Article Open access 05 April 2023 Pages: 425 - 440
A Systematic Evaluation of Cost-Saving Dosing Regimens for Therapeutic Antibodies and Antibody-Drug Conjugates for the Treatment of Lung Cancer Rob ter HeineMichel M. van den HeuvelNikki de Rouw Original Research Article Open access 21 April 2023 Pages: 441 - 450
Uncovering the Burden of Immune-Related Adverse Events in Immunotherapy: Insights from a Nationally Representative Sample Rayli PichardoYazan Abu OmarDing Wang Original Research Article 13 May 2023 Pages: 451 - 461
Trastuzumab Deruxtecan: A Review in Unresectable or Metastatic HER2-Positive Breast Cancer Tina NieHannah A. Blair Adis Drug Evaluation 02 May 2023 Pages: 463 - 470